Murray Passo to Methotrexate
This is a "connection" page, showing publications Murray Passo has written about Methotrexate.
Connection Strength
0.884
-
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 2019 06; 71(6):864-877.
Score: 0.153
-
The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1999 Jan; 134(1):47-52.
Score: 0.150
-
Use of methotrexate in children. Bull Rheum Dis. 1998 Aug; 47(5):1-5.
Score: 0.145
-
The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 1997 Dec; 40(12):2226-34.
Score: 0.139
-
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol Online J. 2017 Jun 13; 15(1):50.
Score: 0.135
-
Emerging therapies in juvenile rheumatoid/idiopathic arthritis. Curr Probl Pediatr Adolesc Health Care. 2006 Mar; 36(3):97-103.
Score: 0.062
-
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003 Feb; 30(2):394-400.
Score: 0.050
-
Parry-Romberg syndrome: follow-up imaging during suppressive therapy. Neuroradiology. 1997 Dec; 39(12):873-6.
Score: 0.035
-
Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006 Sep-Oct; 24(5):599-605.
Score: 0.016